Edesa Biotech Q2 FY2024 net loss $1.9M ($0.58/shr); advances ARDS Phase 3 and vitiligo study

Edesa Biotech, Inc.

Net loss narrowed to $1.9M vs $2.3M YoY; six-month loss $3.5M ($1.12/shr).
Cash $2.8M at March 31; received $0.7M post-quarter from Canadian govt funding.
Expanding Phase 3 ARDS trial with EB05; up to C$23M govt support secured.
Plans to file IND for Phase 2 pulmonary fibrosis study with EB05.
Seeks U.S. approval for Phase 2 vitiligo study; pursuing strategic deals for EB01.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Edesa Biotech, Inc. reported the three and six months ended March 31, 2024 results: net income $1.9 million for the quarter ended March 31, 2024, EPS $0.58 per common share.

Period: the three and six months ended March 31, 2024
Net income: $1.9 million for the quarter ended March 31, 2024
EPS: $0.58 per common share
Result: reported results

Exact text from the filing

For the quarter ended March 31, 2024, Edesa reported a net loss of $1.9 million, or $0.58 per common share

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Edesa Biotech, Inc. reported the six months ended March 31, 2024 results: net income $3.5 million for the six months ended March 31, 2024, EPS $1.12 per common share.

Period: the six months ended March 31, 2024
Net income: $3.5 million for the six months ended March 31, 2024
EPS: $1.12 per common share
Result: reported results

Exact text from the filing

For the six months ended March 31, 2024, Edesa reported a net loss of $3.5 million, or $1.12 per common share

View on SEC.gov

Browse all earnings releases →

Edesa Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-24-005965

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.